Four doses of the drug, ALD403, were tested against a placebo in
patients suffering from chronic migraines.
The trial included patients who experienced 15 or more headache days
per month, of which at least eight were assessed as migraine days.
The two highest doses - 300 mg and 100 mg - of the drug brought
about a 75 percent reduction in migraine days in 33 percent and 31
percent of patients, respectively, the company said.
(Reporting by Natalie Grover in Bengaluru; Editing by Anupama
[© 2016 Thomson Reuters. All rights
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.